Table 3.
Multivariate models of myocardial T1 and ECV adjusting for participant demographics, cardiovascular profile, and parameters associated with LV remodeling.
| Myocardial Native T1 | Myocardial ECV | ||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Model | Covariates | Beta Estimate | (95% CI) | p-value | Beta Estimate | (95% CI) | p-value |
| 1 | Group | <0.0001 | <0.0001 | ||||
| Pre-treatment | 92.7 | (78.3,107.2) | <0.0001 | 0.92 | (−0.44,2.3) | <0.0001 | |
| Post-treatment | 75.3 | (60.6,89.9) | 3.5 | (2.1,5.0) | |||
| 2 | Group | ||||||
| Pre-treatment | 89.9 | (74.6,105.2) | 0.91 | 1.2 | (−0.08,2.6) | <0.01 | |
| Post-treatment | 71.1 | (55.0,87.2) | 0.60 | 3.8 | (2.4,5.2) | 0.77 | |
| Age | 0.41 | (−0.26,1.1) | 0.02 | 0.09 | (0.031,0.14) | <0.01 | |
| Non-white | −2.7 | (−12.5,7.2) | 0.047 | 0.12 | (−0.69,0.93) | 0.08 | |
| Female | 64.7 | (11.0,118.5) | <0.0001 | 6.8 | (2.4,11.3) | <0.0001 | |
| Age*Female | −0.77 | (−1.6,0.05) | −0.06 | (−0.13,0.008) | |||
| 3 | Group | ||||||
| Pre-treatment | 88.9 | (72.5,105.4) | 0.71 | 1.6 | (0.21,3.0) | <0.01 | |
| Post-treatment | 70.0 | (52.3,87.6) | 0.59 | 3.9 | (2.4,5.4) | 0.69 | |
| Age | 0.22 | (−0.49,0.93) | 0.06 | 0.08 | (0.02,0.14) | 0.01 | |
| Non-white | −2.9 | (−13.2,7.5) | 0.15 | 0.17 | (−0.67,1.0) | 0.19 | |
| Female | 54.2 | (−1.8,110.2) | 0.15 | 6.0 | (1.4,10.6) | 0.27 | |
| Age*Female | −0.63 | (−1.5,0.23) | 0.62 | −0.05 | (−0.12,0.02) | 0.22 | |
| Weight | −0.11 | (−0.26,0.04) | 0.77 | −0.01 | (−0.02,0.01) | 0.41 | |
| Systolic BP | −0.08 | (−0.42,0.25) | 0.83 | −0.02 | (−0.05,0.01) | 0.91 | |
| Known CAD | 6.5 | (−37.7,50.7) | 0.46 | −1.6 | (−5.3,2.2) | 0.16 | |
| Diabetes | 1.5 | (−12.0,15.0) | 0.80 | −0.06 | (−1.1,1.0) | 0.67 | |
| Hyperlipidemia | −6.0 | (−21.9,9.9) | <0.0001 | −1.1 | (−2.5,0.41) | <0.0001 | |
| Hypertension | 1.9 | (−13.0,16.9) | 0.28 | (−1.0,1.6) | |||
| 4 | Group | ||||||
| Pre-treatment | 90.0 | (74.5,105.4) | 0.82 | 1.3 | (−0.04,2.6) | <0.01 | |
| Post-treatment | 63.0 | (45.5,80.5) | 0.55 | 4.0 | (2.5,5.5) | 0.70 | |
| Age | 0.40 | (−0.28,1.1) | 0.03 | 0.07 | (0.02,0.13) | <0.01 | |
| Non-white | −3.1 | (−13.1,6.9) | 0.10 | 0.16 | (−0.66,0.98) | 0.16 | |
| Female | 60.8 | (6.0,115.5) | 0.04 | 6.4 | (1.8,11.0) | 0.81 | |
| Age*Female | −0.70 | (−1.5,0.13) | 0.44 | −0.05 | (−0.12,0.02) | 0.46 | |
| LVEF | −0.73 | (−1.4, −0.02) | 0.01 | (−0.05,0.06) | |||
| LV mass index | −0.17 | (−0.60,0.26) | 0.01 | (−0.02,0.05) | |||
Categorical reference variables include no cancer controls (group), white (race), and men (gender). BP=blood pressure; CAD=coronary artery disease; LV=left ventricular; EF=ejection fraction. Post-treatment=anthracycline-treated survivors.